GlassScriptPhysician profile
Luiz A Marconcini
NPI 1801144357
$842.75
in general payments reported to CMS, 2019-2025
19 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2021: $84.35 · 2022: $184 · 2023: $166 · 2024: $50.93 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $127.46 | 2025 | Aliya System |
| Pfizer INC. | $125.42 | 2022-2023 | |
| Lilly USA, LLC | $97.03 | 2019 | |
| Eisai INC. | $68.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.64 | 2022-2024 | |
| Daiichi Sankyo INC. | $46.50 | 2022-2025 | Enhertu |
| Janssen Biotech, INC. | $37.83 | 2021-2025 | Erleada, Balversa |
| Penumbra, INC. | $32.61 | 2022-2023 | Indigo System |
| Genentech USA, INC. | $31.91 | 2019 | |
| Sirtex Medical INC | $29.16 | 2022 | |
| Taiho Oncology, INC. | $26.68 | 2025 | |
| Pharmacosmos Therapeutics INC. | $24.60 | 2022 | |
| Karyopharm Therapeutics INC. | $23.20 | 2025 | Xpovio |
| Beigene USA, INC. | $22.80 | 2023 | Brukinsa |
| Astellas Pharma US INC | $21.85 | 2024 | Xtandi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.56 | 2023 | |
| Ge Healthcare | $19.18 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.04 | 2021 | |
| Recordati_rare_diseases_inc. | $17.60 | 2023 | Panhematin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luiz Marconcini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.